Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand Linker Conjugate
(S,R,S)-AHPC-C7-amine hydrochloride is a novel E3 ligase ligand-linker conjugate that combines a VH032-derived VHL ligand with a C7 linker for targeted protein degradation. Its design facilitates the development of PROTACs targeting estrogen-related receptor α (ERRα), highlighting its utility in research on protein modulation and degradation pathways. This compound serves as a valuable tool in the study of E3 ligase-mediated degradation mechanisms and therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C13-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC degraders, specifically NC-R17. This compound facilitates targeted protein degradation by connecting a ligand for E3 ligases to a protein of interest. Its application in PROTAC technology enables the modulation of protein levels, making it a valuable tool for researchers studying protein regulation and therapeutic degradation strategies. -
E3 Ligase Ligand-Linker Conjugates
(S,S,S)-VH032-cyclopropane-F-C4-aldehyde is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTAC compounds, specifically cis-VZ185. This reagent facilitates targeted protein degradation by engaging with the ubiquitin-proteasome system, making it a valuable tool for researchers investigating protein modulation and degradation pathways. Its unique structure allows for precise conjugation in drug discovery applications focused on cancer and other diseases influenced by protein dysregulation. -
E3 Ligase Ligand-linker Conjugatecan
Boc-4-(3-oxobutyl)piperidine-(S,R,S)-AHPC is a ligand-linker conjugate designed for targeting E3 ligases in protein degradation applications. This compound facilitates the development of proteolysis targeting chimeras (PROTACs), specifically in the synthesis of BRD2 BD1 Degrader-1. It plays a crucial role in selective protein degradation research and expanding therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 176 is designed to bind specifically to E3 ligases, facilitating targeted protein degradation through the ubiquitin-proteasome system. This conjugate enables the synthesis of BMS-986458, allowing for further exploration of E3 ligase modulation in various biological contexts. It is essential for studies focused on protein homeostasis and the therapeutic potential of targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Deoxy-thalidomide-C4-NH2 is a ligand-linker conjugate targeting the E3 ligase Cereblon (CRBN). This compound facilitates the development of Proteolysis Targeting Chimeras (PROTACs), specifically for synthesizing BRD4 degraders. Its unique structure supports targeted protein degradation, making it a valuable tool for research in cellular protein regulation and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-S-C6-acid is a synthetic E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a C6 linker. This compound facilitates the development of PROTACs, specifically designed for targeted protein degradation applications, including the synthesis of the PROTAC Cas9 Degrader-1. Its ability to engage with E3 ligases makes it a valuable tool in biochemistry and molecular biology research focused on therapeutic interventions through targeted protein modulation. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 174 is a specialized reagent designed to target E3 ligases through a ligand-linker conjugate. This compound facilitates the synthesis of the potent compound TYD-68, enabling researchers to explore the role of E3 ligases in ubiquitination processes. Its application in chemical biology can aid in the development of targeted therapies and the study of protein degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-Pip-butyn is an E3 ligase ligand-linker conjugate derived from Lenalidomide. It effectively recruits the CRBN protein, facilitating targeted protein degradation through the formation of proteolysis-targeting chimeras (PROTACs). This reagent is particularly useful for creating PROTACs like the STAT3 degrader SD-436, enabling studies on protein regulation and degradation pathways in cellular models. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG3-COOH is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via the cereblon pathway. This compound integrates a Thalidomide-derived cereblon ligand with a PEG3 linker, optimizing its application in PROTAC (Proteolysis Targeting Chimera) technology. Its unique structure enhances cellular interaction and degradation of specific target proteins, making it a valuable tool for researchers investigating protein regulation and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 218 is designed as a specific ligand-linker construct targeting E3 ligases. This compound plays a crucial role in the development of PROTACs, specifically in the synthesis of STAT6 degrader-2. Researchers can utilize this conjugate to facilitate targeted protein degradation, enhancing studies in protein homeostasis and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-OH-C11-OH is an E3 ligase ligand-linker conjugate designed to recruit the cereblon (CRBN) protein. This compound serves as a crucial intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs), including various targeted degraders. Its application in the development of PROTACs facilitates targeted protein degradation, providing insights into cellular mechanisms and therapeutic opportunities in various diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 170 is a specialized conjugate that facilitates the synthesis of PROTACs by incorporating an E3 ligase ligand with a linker. This compound demonstrates potent anti-proliferative activity in non-Hodgkin's lymphoma cell line SU-DHL-4, exhibiting an IC50 value of less than 0.2 μM. It is an essential tool for researchers investigating targeted protein degradation pathways and their implications in cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-Glycolic acid is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound facilitates the targeted degradation of specific proteins, most notably as a component in the FLT3 degrader LWY713. Its application in research focuses on understanding protein homeostasis and the modulation of oncogenic pathways, making it a valuable tool for drug development in cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-alkyne-C4-NHBoc is an E3 Ligase Ligand-Linker Conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTAC JAK1 degrader 1, enabling the selective degradation of the JAK1 protein. Its utility in research includes studying protein turnover and the therapeutic potential of targeted protein degradation in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-piperazine-Boc is an E3 ligase ligand-linker conjugate designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound facilitates targeted degradation of proteins, enabling researchers to manipulate cellular pathways and study protein function. It serves as a key component in the development of PROTACs, such as PROTAC BET Degrader-15, offering significant potential for applications in therapeutic research and drug discovery. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 115 is a potent E3 ubiquitin ligase ligand combined with a linker, designed for the development of targeted protein degradation strategies. This compound serves as a crucial component in synthesizing PROTAC SMARCA2/4-degrader-27, enabling researchers to investigate the modulation of specific protein levels through ubiquitin-proteasome pathway engagement. Its application in chemical biology provides a valuable tool for studying protein function and regulation in various cellular contexts. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 156 functions as a CRBN E3 ligase ligand-linker conjugate. It serves as a key component in the development of PROTAC (Proteolysis Targeting Chimera) molecules, enabling targeted protein degradation. This compound is particularly relevant for research applications focusing on modulating protein levels in cellular systems, including the synthesis of XPO1 degrader-1. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-amino-PEG4-C4-Cl is an E3 ligase ligand-linker conjugate that features a Pomalidomide-based cereblon (CRBN) ligand. This compound facilitates the development of PROTACs, which are designed to selectively degrade target proteins via the ubiquitin-proteasome pathway. Its chemical structure, incorporating an amino-PEG4 linker, enhances its utility in targeted protein degradation research and other related applications in chemical biology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-amido-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that utilizes a thalidomide-derived cereblon ligand. This compound features a PEG2 linker, facilitating the development of PROTACs for targeted protein degradation. It is valuable in research applications focusing on E3 ligase modulation and therapeutic interventions in cellular protein regulation. -
E3 Ligase Ligand-Linker Conjugate
Succinic acid-Pomalidomide is an E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras). By leveraging the interaction with E3 ligases, this compound facilitates targeted protein degradation, which is a key process in drug discovery and development. Its application is beneficial for researchers focusing on selective modulation of protein levels for therapeutic purposes. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-bis-NH2-C1-PEG3 is a synthesized E3 ligase ligand-linker conjugate designed for the development of PROTACs. This compound facilitates targeted protein degradation through the recruitment of E3 ligases, enabling the selective eradication of specific proteins within cellular systems. Its applications extend to various research areas, including cancer biology and drug discovery, providing a valuable tool for investigating protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-PEG-C2-iodine is a specifically designed E3 ligase ligand-linker conjugate that targets the VHL E3 ubiquitin ligase. This compound facilitates the synthesis of PROTACs, which are engineered to induce targeted protein degradation. It is particularly useful in the development of PROTACs like the FAK degrader 1, enabling researchers to investigate the therapeutic potential of targeted protein degradation in various biological contexts. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 178 is a chemical entity designed to engage with E3 ligases, facilitating targeted protein degradation. This conjugate serves as a versatile tool for synthesizing downstream compounds, notably MS2133. Its application supports research in protein homeostasis and therapeutic development, particularly in the realm of targeted cancer therapies and cellular signaling modulation. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-OCH2-amide-PEG2-C2-Boc is a ligand-linker conjugate designed for E3 ligase targeting, specifically interacting with the cereblon (CRBN) E3 ubiquitin ligase. This compound facilitates the development of PROTACs, including SARS-CoV-2 Degrader-1, making it valuable for research in targeted protein degradation and therapeutic applications against viral infections. Its structural components ensure efficient conjugation for effective modulation of protein levels within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
N-Me-Thalidomide-NH-C6-NH2 is an E3 ligase ligand-linker conjugate designed for the targeted modulation of protein degradation pathways. This compound has demonstrated key biological activity in facilitating the development of novel anti-inflammatory agents, such as Anti-inflammatory agent 70. It serves as an important tool for researchers investigating targeted protein degradation and its therapeutic applications in various inflammatory diseases.
-
E3 Ligase Ligand-Linker Conjugate
(R,S,S)-VH032-Me-glycine is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound enables the synthesis of novel bifunctional molecules, such as XF067-68, which can facilitate selective modulation of protein stability in biological systems. Its utility in creating targeted therapeutic agents makes it valuable for research in drug development and cellular regulation. -
IAP Ligand
A 410099.1, amine-Boc is a functionalized inhibitor of apoptosis protein (IAP) ligand that serves as a valuable building block for synthesizing proteolysis-targeting chimeras (PROTACs). This compound is particularly useful in the development of PROTACs that target Bruton's tyrosine kinase (BTK), showing promise for applications in cancer research and therapeutic development. Its ability to help modulate protein degradation makes it a potent tool in the exploration of novel treatment strategies. -
E3 Ligase Ligand-Linker Conjugate
DHFR-IN-5-amino-PEG3-C2-azido is an E3 ligase ligand-linker conjugate designed for the synthesis of BION106, a potent DHFR-TS PROTAC degrader. This compound exhibits significant anti-malarial activity, making it a valuable tool in research focused on targeted protein degradation and parasitic diseases. Its unique structure facilitates the development of innovative therapeutic approaches in the field of drug discovery and development. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C2-NH2 is an E3 ligase ligand-linker conjugate that incorporates the VH032-derived VHL ligand, designed for applications in targeted protein degradation via PROTAC technology. This compound facilitates the recruitment of E3 ligases to target proteins, enabling efficient ubiquitination and subsequent proteasomal degradation. Its use in research can enhance the understanding of protein dynamics and assist in the development of therapeutics aimed at regulating protein levels in various disease contexts. -
E3 ligase ligand-linker conjugate
E3 Ligase Ligand-linker Conjugate 215 is designed as a specific E3 ligase ligand-linker conjugate. This compound facilitates the synthesis of STAT3 PROTAC Degrader S3D5, enabling selective degradation of the STAT3 protein. It serves as a valuable tool in research focused on targeted protein degradation and the modulation of cellular signaling pathways related to oncogenesis and inflammation. -
Vhl Ligand-Linker Conjugate
(S,R,S)-AHPC-C3-COOH is a carboxylic acid derivative targeting the VHL E3 ubiquitin ligase, functioning as a ligand-linker conjugate. This compound is instrumental in the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation for potential therapeutic applications. Its structural properties make it a valuable tool in chemical biology for exploring ubiquitin-mediated proteolysis and developing innovative strategies in drug discovery. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 186 is designed as a CRBN E3 ligase ligand-linker conjugate. This reagent facilitates the synthesis of targeted protein degraders, specifically enabling the formation of PROTAC SJ10542. Its application extends to studies involving protein modulation and targeted degradation within cellular systems, making it a crucial component for research in therapeutic development and cellular regulation. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C9-Br is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology, incorporating the Thalidomide-derived CRBN ligand. This compound facilitates the targeted degradation of specific proteins by connecting to a ligand through a linker, enabling the formation of PROTAC EZH2 Degrader-19. Thalidomide-4-O-C9-Br is essential for researchers investigating targeted protein degradation and protein homeostasis in cellular systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Pip-N-boc is an E3 ligase ligand-linker conjugate, specifically designed for targeted protein degradation applications. This compound facilitates the synthesis of the PROTAC Degrader LLC0424, enabling researchers to investigate protein modulation and degradation pathways. Its role as a linker enhances the efficiency of targeted therapies in chemical biology studies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-amide-C4-Br is a conjugate that features a VHL ligand specifically designed for E3 ubiquitin ligase targeting, along with a PROTAC linker. This compound serves as a crucial building block for the development of PROTACs, facilitating targeted protein degradation. It can be utilized in research applications focused on inducing degradation of select proteins, such as in the synthesis of PROTAC ERK5 degrader-1. -
Conjugate
Lenalidomide-C6-NH2 is a conjugate designed to target E3 ligases through a chemically defined linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling the selective degradation of target proteins. Its application is pivotal in the development of innovative therapeutic strategies for various diseases, including cancer. -
E3 Ligase Ligand-linker Conjugate
Lenalidomide-C7-NH2 is a synthetic E3 ligase ligand-linker conjugate designed for the development of PROTACs. This compound facilitates the targeted degradation of proteins by enabling the formation of PROTACs, such as GXF-111, which specifically degrades BRD3 and BRD4 proteins. With demonstrated anti-tumor activity, Lenalidomide-C7-NH2 serves as an essential tool for advancing research in targeted protein degradation and cancer therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that utilizes the (S,R,S)-AHPC-based VHL ligand, designed for targeted protein degradation applications. This compound serves as an essential component in PROTAC (Proteolysis Targeting Chimera) technology, facilitating the selective ubiquitination and degradation of target proteins. Its integration into research workflows can enhance studies focused on protein modulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
5-Aminothalidomide-cyclohexane is a conjugate designed for targeting E3 ligases. This compound serves as a ligand-linker, facilitating the recruitment of E3 ligases in protein degradation applications. Its key biological activity enables the modulation of cellular pathways, making it a valuable tool in chemical biology and drug discovery research. Researchers can utilize this compound to study ubiquitin-proteasome system dynamics and explore potential therapeutic interventions. -
PROTAC E3 Ligases and Linkers
OTs-PEG3-NHCO-Thalidomide is a compound that serves as a linker for PROTAC (Proteolysis Targeting Chimera) technologies, specifically targeting ubiquitin E3 ligases. It is designed to facilitate the degradation of α-synuclein, making it valuable for research focused on neurodegenerative diseases. This reagent enables the development of targeted protein degradation strategies, contributing to advances in therapeutic approaches for conditions such as Parkinson's disease. -
E3 Ligase Ligand-Linker Conjugates
Boc-A 410099.1 amide-alkylC4-amine is a functionalized ligand for E3 ligase utilized in PROTAC (Proteolysis Targeting Chimera) technology. This compound features an IAP ligand coupled with an amide-alkylC4 linker, which includes a terminal amine suitable for effective conjugation with target protein ligands. Its design enables precise modulation of targeted protein degradation, making it valuable for research in targeted therapy development and mechanistic studies of protein turnover. -
E3 ligase ligand-Linker Conjugate
Thalidomide-4-O-C10-Br is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via PROTAC technology. This compound incorporates a thalidomide-derived CRBN ligand, enabling the selective degradation of target proteins. Thalidomide-4-O-C10-Br can be utilized in the construction of PROTAC EZH2 Degrader-22, allowing for innovative research in the regulation of protein homeostasis and the exploration of therapeutic strategies against various diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 173 functions as a specialized ligand-linker conjugate for E3 ligases, facilitating targeted protein degradation. This compound can be utilized to synthesize YN14-H, which demonstrates the ability to induce apoptosis and inhibit cellular migration. Its application in research includes the exploration of antitumor mechanisms in vivo, providing valuable insights into cancer treatment strategies.
-
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 128 is an advanced conjugate designed to interact with E3 ligases, facilitating targeted protein degradation. This compound is primarily utilized in the synthesis of proteolysis-targeting chimeras (PROTACs), specifically for the generation of BRM/BRG1 degrader-4. Its unique properties enable researchers to explore innovative strategies for modulating protein levels, making it a valuable tool in cellular biology and drug discovery research. -
E3 Ligase Ligand-Linker Conjugate
Me-(S,R,S)-AHPC-CO-CH2-PEG4-O-CH2-COOH is a specialized E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound serves as a crucial building block for the synthesis of PROTAC degraders, such as MS4322, facilitating the selective degradation of specific proteins within cellular environments. It is ideal for researchers investigating targeted protein modulation and the development of innovative therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-CO-C5-Br is an E3 ligase ligand-linker conjugate that facilitates the development of PROTAC (Proteolysis Targeting Chimeras) molecules. This compound combines the pharmacological properties of Pomalidomide with a C5 linker, enabling targeted degradation of specific proteins through the ubiquitin-proteasome system. Its application in research offers promising avenues for cancer treatment and other disorders by enhancing the selectivity and efficacy of targeted therapies. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-Me-N-Boc-7-aminoheptanoic acid serves as a bifunctional linker that facilitates the development of E3 ligase ligand-conjugates. Its primary role is to enable the synthesis of targeted protein degradation agents, specifically PROTAC dTAGV-1 TFA. This reagent is essential in studies focused on protein regulation and degradation pathways, contributing to advances in therapeutic development and cellular research. -
E3 Ligase Ligand-linker Conjugate
CBP-IN-1 acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs, including the potent CBP/p300 degrader, CBPD-268. This compound exhibits significant anti-cancer activity by facilitating the targeted degradation of CBP/p300 proteins. It serves as a valuable tool for researchers exploring targeted protein degradation and its implications in cancer therapies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C11-acid is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a substrate receptor for E3 ligases. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology and facilitates the targeted degradation of proteins through the ubiquitin-proteasome system. It serves as a valuable tool for research into proteostasis and potential therapeutic interventions.
